Evidence map›Paper›PMID 42057038›Full record

ArticleJournal of nanobiotechnology2026

Biomimetic PD-1 macrophage nanoplatform for Cip2a silencing and immune activation in oral squamous cell carcinoma.

Chenyu Zhang, Zhe Yuan, Jie Zhou, Huizhu Yan, Zhong Liu, Xinyue Zhang, Yuxia Zhang, Shuo Zhang, Lijuan Zhu, Dali Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chenyu Zhang *Department of Oral and Maxillofacial Surgery, School of Stomatology, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, P. R. China.
Zhe Yuan *Department of Oral and Maxillofacial Surgery, School of Stomatology, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, P. R. China.
Jie ZhouDepartment of Oral and Maxillofacial Surgery, School of Stomatology, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, P. R. China.
Huizhu YanDepartment of Oral and Maxillofacial Surgery, School of Stomatology, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, P. R. China.
Zhong LiuDepartment of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, P. R. China.
Xinyue ZhangState Key Laboratory of Synergistic Chem-Bio Synthesis, School of Chemistry and Chemical Engineering, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, P. R. China.
Yuxia ZhangDepartment of Oral and Maxillofacial Surgery, School of Stomatology, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, P. R. China.
Shuo ZhangDepartment of Oral and Maxillofacial Surgery, School of Stomatology, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, P. R. China.
Lijuan ZhuInstitute of Photochemistry and Photofunctional Materials, School of Materials and Chemistry, University of Shanghai for Science and Technology, 516 Jungong Road, 200093, Shanghai, P. R. China. lijuanzhu@sjtu.edu.cn.
Dali WangState Key Laboratory of Synergistic Chem-Bio Synthesis, School of Chemistry and Chemical Engineering, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, P. R. China. energywang@sjtu.edu.cn.
Bing LiuDepartment of Oral and Maxillofacial Surgery, School of Stomatology, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, P. R. China. liubingdoctor123@126.com.

Funding

Medicine Engineering joint foundation of Shanghai Jiao Tong University YG2024ZD15National Natural Science Foundation of China 22375126National Natural Science Foundation of China 22575150National Natural Science Foundation of China 82272674Outstanding Youth Foundation of Heilongjiang Provincial Natural Science Foundation YQ2023H010Research Project of the First Affiliated Hospital of Harbin Medical University 2021J04
6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) remains a highly aggressive malignancy in which immune checkpoint blockade alone shows limited efficacy due to persistent tumor-intrinsic survival signaling and an immunosuppressive tumor microenvironment. Here, we report a biomimetic nanoplatform, siCip2a@PML, designed to integrate tumor-intrinsic apoptosis induction with immune checkpoint blockade. Cancerous inhibitor of protein phosphatase 2A (Cip2a) siRNA (siCip2a) is encapsulated within lipid nanoparticles to suppress OSCC cell growth through apoptosis induction, while the nanoparticles are cloaked with PD-1-overexpressing macrophage membrane to enable tumor targeting and competitive blockade of PD-1/PD-L1 signaling. The rationale for this combinatorial strategy is supported by clinical specimen analysis and The Cancer Genome Atlas (TCGA) data, which reveal elevated expression of Cip2a and PD-L1 in OSCC and their association with poor prognosis. siCip2a@PML exhibits enhanced tumor accumulation, efficient gene silencing, and potent antitumor activity in vitro and in vivo. Importantly, PD-1-functionalized membrane camouflage promotes dendritic cells maturation, increases intratumoral infiltration of CD4⁺ and CD8⁺ T cells, and restores antitumor immune responses. By uniting tumor-intrinsic growth suppression with immune checkpoint modulation in a single delivery system, this work presents a clinically informed gene-immunotherapy strategy and offers a promising therapeutic paradigm for OSCC.

Indexed as

AutoantigensCarcinoma, Squamous CellMacrophagesMembrane ProteinsMouth NeoplasmsNanoparticlesProgrammed Cell Death 1 ReceptorAnimalsApoptosisB7-H1 AntigenBiomimetic MaterialsBiomimeticsCell Line, TumorFemaleGene SilencingHumansAutoantigensB7-H1 AntigenCIP2A protein, humanIntracellular Signaling Peptides and ProteinsMembrane ProteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorRNA, Small InterferingBiomimetic nanoplatformCip2aDrug deliveryGene–immunotherapyOral squamous cell carcinoma

Identifiers

PMID42057038
PMCPMC13274171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.